Literature DB >> 27539324

Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.

Reshma Pandit1, Kranti Khadilkar2, Vijaya Sarathi3, Rajeev Kasaliwal4, Manjunath Goroshi2, Shruti Khare2, Sandhya Nair2, Vijaya Raghavan2, Abhay Dalvi5, Priya Hira6, Gwendolyn Fernandes7, Pragati Sathe7, Amey Rojekar7, Gaurav Malhotra8, Ganesh Bakshi9, Gagan Prakash9, Anil Bhansali10, Rama Walia10, Sadishkumar Kamalanathan11, Jayaprakash Sahoo11, Ankush Desai12, Nikhil Bhagwat13, Prashanth Mappa14, Rajesh Rajput15, Sudha Rao Chandrashekhar16, Vyankatesh Shivane2, Padma Menon2, Anurag Lila2, Tushar Bandgar2, Nalini Shah2.   

Abstract

BACKGROUND: Genetic aetiology of pheochromocytoma (PCC) and paraganglioma (PGL) is increasingly being studied; however, Asian Indian data on this aspect are scarce.
OBJECTIVE: To study the prevalence of germline mutations and genotype-phenotype correlation in Asian Indian PCC/PGL patients.
DESIGN: In this study, 150 index patients (M:F, 73:77) with PCC/PGL were evaluated. Phenotypic data were collected. Germline mutations in five susceptibility genes (RET, VHL, SDHB, SDHD and SDHC) were tested by sequencing and NF1 was diagnosed according to phenotype. RESULT: Of the total population, 49 (32.7%) PCC/PGL patients had germline mutations (VHL: 23 (15.3%), RET: 13 (8.7%), SDHB: 9 (6%), SDHD: 2 (1.3%) and NF1: 2 (1.3%)). Amongst the 30 patients with familial and/or syndromic presentation, all had germline mutations (VHL: 14 (46.7%), RET: 13 (43.3%), SDHB: 1 (3.3%) and NF1: 2 (6.7%)). Out of 120 patients with apparently sporadic presentation, 19 (15.8%) had a germline mutation (VHL: 9 (7.5%), SDHB: 8 (6.7%) and SDHD: 2 (1.7%)). Mutation carriers were younger (29.9 ± 14.5 years vs 36.8 ± 14.9; P = 0.01) and had a higher prevalence of bilateral PCC (26.5% vs 2.9%, P < 0.001) and multifocal tumours (12.2% vs 0.96%, P = 0.06). Based on syndromic features, metastasis, location and number of tumours, around 96% mutations in our cohort could be detected by appropriately selected single gene testing.
CONCLUSION: Asian Indians with PCC/PGL differ from Western cohorts in having preponderance of VHL mutations in multifocal tumours and apparently sporadic unilateral PCC. Syndromic presentation, metastasis, location and number of PCC/PGL can be effectively used for guiding genetic prioritisation.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27539324     DOI: 10.1530/EJE-16-0126

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

1.  Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.

Authors:  Nilesh Lomte; Sanjeet Kumar; Vijaya Sarathi; Reshma Pandit; Manjunath Goroshi; Swati Jadhav; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

2.  ISOLATED PARAGANGLIOMA IN A PATIENT WITH VHL P.L163F MUTATION.

Authors:  Michael Goldstein; Rebecca E Neril; Gary D Rothberger
Journal:  AACE Clin Case Rep       Date:  2020-05-04

3.  Carotid body tumor with neck metastasis due to germline SDHB variant: a case report and literature review.

Authors:  Takuya Mikoshiba; Keisuke Yoshihama; Fumihiro Ito; Mariko Sekimizu; Shintaro Nakamura; Ryoto Nagai; Takenori Akiyama; Kentaro Matsubara; Hideaki Obara; Hiroyuki Ozawa
Journal:  Int Cancer Conf J       Date:  2021-10-31

4.  Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience.

Authors:  Kranti Khadilkar; Vijaya Sarathi; Rajeev Kasaliwal; Reshma Pandit; Manjunath Goroshi; Gaurav Malhotra; Abhay Dalvi; Ganesh Bakshi; Anil Bhansali; Rajesh Rajput; Vyankatesh Shivane; Anurag Lila; Tushar Bandgar; Nalini S Shah
Journal:  Endocr Connect       Date:  2016-11-16       Impact factor: 3.335

Review 5.  Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers.

Authors:  Mei Yin Wong; Katrina A Andrews; Benjamin G Challis; Soo-Mi Park; Carlo L Acerini; Eamonn R Maher; Ruth T Casey
Journal:  Clin Endocrinol (Oxf)       Date:  2019-01-29       Impact factor: 3.478

6.  One genotype, many phenotypes: SDHB p.R90X mutation-associated paragangliomas.

Authors:  Ali S Alzahrani; Meshael Alswailem; Yosra Moria; Ayman Aldeheshi; Hindi Al-Hindi
Journal:  Endocrine       Date:  2020-08-17       Impact factor: 3.633

7.  Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.

Authors:  Shatha Albattal; Meshael Alswailem; Yosra Moria; Hindi Al-Hindi; Majed Dasouki; Mohamed Abouelhoda; Hala Aba Alkhail; Entissar Alsuhaibani; Ali S Alzahrani
Journal:  Oncotarget       Date:  2019-10-15

8.  177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma.

Authors:  Sanjeet Kumar Jaiswal; Vijaya Sarathi; Saba Samad Memon; Robin Garg; Gaurav Malhotra; Priyanka Verma; Ravikumar Shah; Manjeet Kaur Sehemby; Virendra A Patil; Swati Jadhav; Anurag Ranjan Lila; Nalini S Shah; Tushar R Bandgar
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

9.  Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.

Authors:  Weenita Pipitprapat; Oraluck Pattanaprateep; Nareenart Iemwimangsa; Insee Sensorn; Bhakbhoom Panthan; Poramate Jiaranai; Wasun Chantratita; Kinnaree Sorapipatcharoen; Preamrudee Poomthavorn; Pat Mahachoklertwattana; Thanyachai Sura; Atchara Tunteeratum; Kanoknan Srichan; Chutintorn Sriphrapradang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

10.  Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?

Authors:  Aylin Ege Gul; Sevinc Hallac Keser; Nagehan Ozdemir Barisik; Yesim Saliha Gurbuz; Sibel Sensu; Nusret Erdogan
Journal:  Asian Pac J Cancer Prev       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.